- Home
- Publications
- Publication Search
- Publication Details
Title
New drugs for NASH
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 41, Issue S1, Pages 112-118
Publisher
Wiley
Online
2021-06-22
DOI
10.1111/liv.14844
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New drugs for non‐alcoholic steatohepatitis
- (2020) Ana‐Carolina Cardoso et al. LIVER INTERNATIONAL
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
- (2020) Beth A. Davison et al. JOURNAL OF HEPATOLOGY
- Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
- (2020) Federica Saponaro et al. Frontiers in Medicine
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Novel MRI assessment of treatment response in HIV ‐associated NAFLD : a randomized trial of an SCD 1 inhibitor ( ARRIVE Trial)
- (2019) Veeral H. Ajmera et al. HEPATOLOGY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Development of new drugs for the treatment of nonalcoholic steatohepatitis
- (2019) Jie Ting Tang et al. Journal of Digestive Diseases
- Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
- (2018) Zobair Younossi et al. Clinical Gastroenterology and Hepatology
- MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
- (2018) Jerry R. Colca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States
- (2018) Neehar D. Parikh et al. HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
- (2017) Manan Jhaveri et al. Therapeutics and Clinical Risk Management
- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
- (2016) Eric Lefebvre et al. PLoS One
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways
- (2013) Daniel F. Vatner et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
- (2010) Alicia Leikin-Frenkel et al. ARCHIVES OF MEDICAL RESEARCH
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now